Trial watch: dendritic cell vaccination for cancer immunotherapy

References 407

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

60. 60.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

65. 65.
    Targeting Antigens to Dendritic Cell Receptors for Vaccine Development · 2013

    No notice
66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

75. 75.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

76. 76.
    Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity · 2013

    No notice
77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

85. 85.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

89. 89.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

100. 100.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

101. 101.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

102. 102.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

103. 103.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

104. 104.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

105. 105.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

106. 106.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

107. 107.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

108. 108.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

109. 109.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

110. 110.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

111. 111.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

112. 112.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

113. 113.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

114. 114.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

115. 115.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

116. 116.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

117. 117.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

118. 118.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

119. 119.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

120. 120.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

121. 121.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

122. 122.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

123. 123.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

124. 124.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

125. 125.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

126. 126.
     Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death · 2015

     No notice
127. 127.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

128. 128.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

129. 129.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

130. 130.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

131. 131.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

132. 132.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

133. 133.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

134. 134.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

135. 135.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

136. 136.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

137. 137.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

138. 138.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

139. 139.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

140. 140.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

141. 141.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

142. 142.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

143. 143.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

144. 144.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

145. 145.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

146. 146.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

147. 147.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

148. 148.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

149. 149.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

150. 150.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

151. 151.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

152. 152.
     Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy · 2017

     No notice
153. 153.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

154. 154.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

155. 155.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

156. 156.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

157. 157.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

158. 158.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

159. 159.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

160. 160.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

161. 161.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

162. 162.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

163. 163.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

164. 164.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

165. 165.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

166. 166.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

167. 167.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

168. 168.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

169. 169.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

170. 170.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

171. 171.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

172. 172.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

173. 173.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

174. 174.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

175. 175.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

176. 176.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

177. 177.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

178. 178.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

179. 179.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

180. 180.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

181. 181.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

182. 182.
     Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer · 2017

     No notice
183. 183.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

184. 184.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

185. 185.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

186. 186.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

187. 187.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

188. 188.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

189. 189.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

190. 190.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

191. 191.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

192. 192.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

193. 193.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

194. 194.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

195. 195.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

196. 196.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

197. 197.
     A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients · 2017

     No notice
198. 198.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

199. 199.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

200. 200.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

201. 201.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

202. 202.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

203. 203.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

204. 204.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

205. 205.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

206. 206.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

207. 207.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

208. 208.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

209. 209.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

210. 210.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

211. 211.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

212. 212.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

213. 213.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

214. 214.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

215. 215.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

216. 216.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

217. 217.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

218. 218.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

219. 219.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

220. 220.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

221. 221.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

222. 222.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

223. 223.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

224. 224.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

225. 225.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

226. 226.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

227. 227.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

228. 228.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

229. 229.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

230. 230.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

231. 231.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

232. 232.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

233. 233.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

234. 234.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

235. 235.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

236. 236.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

237. 237.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

238. 238.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

239. 239.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

240. 240.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

241. 241.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

242. 242.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

243. 243.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

244. 244.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

245. 245.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

246. 246.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

247. 247.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

248. 248.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

249. 249.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

250. 250.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

251. 251.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

252. 252.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

253. 253.
     Cancer immunotherapy beyond immune checkpoint inhibitors · 2018

     No notice
254. 254.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

255. 255.
     NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control · 2018

     No notice
256. 256.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

257. 257.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

258. 258.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

259. 259.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

260. 260.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

261. 261.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

262. 262.
     Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer · 2018

     No notice
263. 263.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

264. 264.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

265. 265.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

266. 266.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

267. 267.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

268. 268.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

269. 269.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

270. 270.
     Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance · 2018

     No notice
271. 271.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

272. 272.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

273. 273.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

274. 274.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

275. 275.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

276. 276.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

277. 277.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

278. 278.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

279. 279.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

280. 280.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

281. 281.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

282. 282.
     First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma · 2018

     Corrected
283. 283.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

284. 284.
     Mechanisms of immune evasion in breast cancer · 2018

     No notice
285. 285.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

286. 286.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

287. 287.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

288. 288.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

289. 289.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

290. 290.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

291. 291.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

292. 292.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

293. 293.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

294. 294.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

295. 295.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

296. 296.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

297. 297.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

298. 298.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

299. 299.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

300. 300.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

301. 301.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

302. 302.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

303. 303.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

304. 304.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

305. 305.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

306. 306.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

307. 307.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

308. 308.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

309. 309.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

310. 310.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

311. 311.
     The Role of Type 1 Conventional Dendritic Cells in Cancer Immunity · 2018

     No notice
312. 312.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

313. 313.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

314. 314.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

315. 315.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

316. 316.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

317. 317.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

318. 318.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

319. 319.
     Cytokines in clinical cancer immunotherapy · 2018

     No notice
320. 320.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

321. 321.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

322. 322.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

323. 323.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

324. 324.
     Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients · 2018

     No notice
325. 325.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

326. 326.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

327. 327.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

328. 328.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

329. 329.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

330. 330.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

331. 331.
     Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? · 2018

     No notice
332. 332.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

333. 333.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

334. 334.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

335. 335.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

336. 336.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

337. 337.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

338. 338.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

339. 339.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

340. 340.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

341. 341.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

342. 342.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

343. 343.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

344. 344.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

345. 345.
     Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? · 2019

     No notice
346. 346.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

347. 347.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

348. 348.
     Immune Cell Composition in Human Non-small Cell Lung Cancer · 2019

     No notice
349. 349.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

350. 350.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

351. 351.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

352. 352.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

353. 353.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

354. 354.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

355. 355.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

356. 356.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

357. 357.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

358. 358.
     Monocyte heterogeneity and functions in cancer · 2019

     No notice
359. 359.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

360. 360.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

361. 361.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

362. 362.
     Regulatory cytokine function in the respiratory tract · 2019

     No notice
363. 363.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

364. 364.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

365. 365.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

366. 366.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

367. 367.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

368. 368.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

369. 369.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

370. 370.
     Personalized Dendritic Cell Vaccines—Recent Breakthroughs and Encouraging Clinical Results · 2019

     No notice
371. 371.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

372. 372.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

373. 373.
     Sources of Type I Interferons in Infectious Immunity: Plasmacytoid Dendritic Cells Not Always in the Driver's Seat · 2019

     No notice
374. 374.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

375. 375.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

376. 376.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

377. 377.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

378. 378.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

379. 379.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

380. 380.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

381. 381.
     The clinical application of cancer immunotherapy based on naturally circulating dendritic cells · 2019

     No notice
382. 382.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

383. 383.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

384. 384.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

385. 385.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

386. 386.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

387. 387.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

388. 388.
     Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen · 2019

     No notice
389. 389.
     STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models · 2019

     No notice
390. 390.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

391. 391.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

392. 392.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

393. 393.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

394. 394.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

395. 395.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

396. 396.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

397. 397.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

398. 398.
     Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy · 2020

     No notice
399. 399.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

400. 400.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

401. 401.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

402. 402.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

403. 403.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

404. 404.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

405. 405.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

406. 406.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

407. 407.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

Cited by papers we hold 6

• Cancer vaccines as promising immuno-therapeutics: platforms and current progress · 2022
  No notice
• DC-Based Vaccines for Cancer Immunotherapy · 2020
  No notice
• Necroptosis in Immuno-Oncology and Cancer Immunotherapy · 2020
  No notice
• Detection of immunogenic cell death and its relevance for cancer therapy · 2020
  No notice
• Consensus guidelines for the definition, detection and interpretation of immunogenic cell death · 2020
  Corrected
• Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.